Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458 is registered in ClinicalTrials.gov with Hearn Jay Cho as lead sponsor.

NCT NCT02655458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02655458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of Elotuzumab in Combination With Autologous Stem Cell Transplantation and Lenalidomide Maintenance for Multiple Myeloma
Lead sponsor
Hearn Jay Cho
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2016
Completion date
July 13, 2017
Enrollment
15 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma